Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Orexo AB ( (SE:ORX) ) has shared an announcement.
Orexo AB announced its participation in the 16th Annual Healthcare Conference organized by Pareto Securities, scheduled for September 16, 2025, in Stockholm, Sweden. During the event, Robert Rönn, SVP and Head of R&D, will present the company’s developments, and both he and Lena Wange, Investor Relations Director, will be available for one-on-one meetings. This participation highlights Orexo’s ongoing engagement with the healthcare investment community and its commitment to showcasing its advancements in pharmaceutical solutions, potentially enhancing its industry positioning and stakeholder relations.
The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK23.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.
More about Orexo AB
Orexo is a Swedish pharmaceutical company with 30 years of experience in developing improved pharmaceuticals using proprietary formulation technologies. It focuses on providing innovative treatment solutions for opioid use disorder in the US market and develops products for other therapeutic areas globally with leading partners. In 2024, Orexo reported total net sales of SEK 590 million and employed 110 people. The company is listed on Nasdaq Stockholm and available as ADRs on the OTCQX market in the US.
YTD Price Performance: 33.43%
Average Trading Volume: 27,413
Technical Sentiment Signal: Buy
Current Market Cap: SEK800.8M
See more insights into ORX stock on TipRanks’ Stock Analysis page.